The company is focused on discovering a novel pathway for neuroprotection and neuroregeneration of degenerating neurons, with a particular focus on diabetic peripheral neuropathy, chemo-induced peripheral neuropathy, HIV-induced and others. WinSanTor was founded by scientists and industry experts who are pursuing a science-driven approach to translational medicine and clinical development, with the goal of developing effective medicines to prevent and reverse nerve damage caused by these conditions. The company has patented their new formulation with novel indications, offering patients a promising new option for the treatment of peripheral neuropathies.